Breast Cancer
Conditions
Keywords
stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer
Brief summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Detailed description
OBJECTIVES: * Identify women who are resistant to tamoxifen citrate and other drugs for the treatment of breast cancer by testing their plasma for the presence of proteins (e.g., macrophage migration inhibition factor) encoded by resistance-inducing genes (RIGs). * Provide retrospective data on the predictive value of RIGs to serve as the basis for a prospective clinical trial of these genes as predictors of drug resistance. OUTLINE: This is a multicenter study. Patients are stratified according to response during tamoxifen citrate (TAM) therapy (resistant group \[i.e., those who develop recurrent breast cancer while being treated with TAM\] vs conditionally sensitive group \[i.e., those who have disease-free survival for over 3 years after initial diagnosis while being treated with TAM\]). Patients undergo blood collection at baseline, within 3 weeks of initiation of TAM therapy, and then every 6 months for 3 years or until relapse, whichever comes first. Samples are analyzed by enzyme-linked immunosorbent assay for expression of protein biomarkers (i.e., kallikrein gene 10, macrophage migration inhibition factor, prolyl carboxypeptidase, queuine tRNA-ribosyltransferase, and kinesin) encoded by resistance-inducing genes. An additional blood sample is obtained from patients at the time of relapse, if available. Patients also undergo assessment of medical history, personal habits, and characteristics of breast cancer (e.g., tumor histology, stage, and grade) at baseline.
Interventions
DRUGtamoxifen citrate
GENETICgene expression analysis
GENETICprotein expression analysis
OTHERimmunoenzyme technique
OTHERlaboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed invasive breast cancer * Initial pathologic stage I-IIIB disease * No stage IV disease * Meets the following criteria for breast cancer therapy: * Received prior primary local therapy for breast cancer * Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks * Hormone receptor status: * Estrogen-receptor positive tumor * Female * Pre- or post-menopausal * Must be able to donate 20 mL of blood
Exclusion criteria
* Severe anemia, defined as hemoglobin \< 11 g/dL * Psychiatric history that would preclude obtaining informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the mechanisms of tamoxifen citrate (TAM) resistance in breast cancer | — |
| Change in expression levels of protein biomarkers of TAM resistance as measured periodically for 3 years or until relapse, whichever comes first | — |
| Retrospective data on the predictive value of resistance-inducing genes | — |
Countries
United States
Outcome results
None listed